Medical Sciences
Baseline Tumor Transcriptional Features and Event-Free Survival After Anti-CD19 CAR T-Cell Therapy with Axicabtagene Ciloleucel in Large B-Cell Lymphoma: An Exploratory Reanalysis of the Randomized ZUMA-7 Trial
By Jean Silva de Souza Resende, Igor Samesima Giner, Maria Gabriela Custódio de Figueiredo and 4 others.
Abstract
Background/Objectives: Anti-CD19 chimeric antigen receptor (CAR) T-cell therapy with axicabtagene ciloleucel (axi-cel) improves outcomes in relapsed/refractory large B-cell lymphoma (LBCL), but many patients relapse despite retained CD19 expression. We explored baseline tumor transcriptional features associated with event-free survival (EFS) after axi-cel.
